Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Portfolio Pulse from Lisa Levin
The article lists the stocks that have gained and lost the most in Thursday's mid-day session. Some of the top gainers include Femasys Inc., Ultralife Corporation, and Mallinckrodt plc, while the top losers include Mersana Therapeutics, Inc., Yellow Corporation, and Asensus Surgical, Inc. The reasons for the changes in stock prices range from better-than-expected quarterly results to reports of potential bankruptcy.
July 27, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Femasys Inc. reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control, causing its stock to gain 54%.
The notice of allowance for a new patent application is a positive development for Femasys Inc., which could potentially increase its revenue and profitability in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Mallinckrodt plc's shares gained 36.5% following a report suggesting the company is considering bankruptcy as part of a plan to avoid opioid payments.
The potential bankruptcy could help Mallinckrodt plc avoid significant financial liabilities related to opioid payments, which is seen as a positive development by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ultralife Corporation's shares jumped 43.4% after the company posted better-than-expected second-quarter results.
Better-than-expected quarterly results indicate that Ultralife Corporation is performing well, which increases investor confidence and drives up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Asensus Surgical, Inc.'s stock fell 33.3% as the company reported a $10 million registered direct offering.
The registered direct offering could potentially dilute the shares of Asensus Surgical, Inc., which is a negative development for existing shareholders.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Mersana Therapeutics, Inc.'s shares dipped 76.3% after the company said UPLIFT clinical trial of upifitamab rilsodotin did not meet primary endpoint.
The failure of the UPLIFT clinical trial to meet its primary endpoint is a negative development for Mersana Therapeutics, Inc., which could potentially impact its future revenue and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Yellow Corporation's stock fell 55.4% as the company is preparing to file for bankruptcy, according to the Wall Street Journal.
The potential bankruptcy is a negative development for Yellow Corporation, which could lead to significant financial losses for the company and its shareholders.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100